NASDAQ$ATXS
Astria Therapeutics Inc · Q2 2025 earnings
Q2 2025 earnings · · After market close · Investor relations
Briefing
Astria Therapeutics reported Q2 2025, net loss of $33.05B.
For Q2 2025, Astria Therapeutics reported a net loss of $33.05B. The filing discusses segment trends, liquidity, and management outlook for upcoming periods.
- Net loss $33.05B.
- Astria Therapeutics highlights operating priorities and capital allocation.
- Astria Therapeutics highlights operating priorities and capital allocation.
Headline financials
Revenue & EPS history
Astria · Revenue · Quarterly
$0
Forward guidance
The release discusses Astria Therapeutics's outlook, capital allocation, and key risks for upcoming quarters, including guidance ranges or operating priorities where disclosed.
Tailwinds
- Astria Therapeutics cites demand and execution supporting the near-term outlook.
- Liquidity and balance-sheet capacity support operations and shareholder returns.
Headwinds
- GAAP profitability remained under pressure in Q2 2025.
- Macro, input costs, and FX may pressure margins quarter to quarter.
- Segment mix and one-time items can affect comparability versus prior periods.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 7 quarterly earnings reports · overlaid with Q2 2025
+1.3%
Avg return
Earnings day
+1.4%
Avg return
5 days after
+0.6%
Avg return
30 days after
52%
22 / 42 earnings
Positive
+19.8%
Q4 2018
Best reaction
-11.6%
Q2 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | — | — | — | |
| Q3 2025 | +0.2% | +0.5% | +3.3% | |
| Q2 2025 | +3.0% | +1.7% | +11.7% | |
| Q1 2025 | +7.3% | +2.8% | +49.7% | |
| Q4 2024 | +11.2% | +10.8% | -30.2% | |
| Q3 2024 | -9.6% | -17.8% | -14.7% | |
| Q2 2024 | +10.9% | +18.4% | +12.1% | |
| Q1 2024 | +1.7% | -0.9% | -7.6% | |
| Q4 2023 | -7.5% | -4.1% | -19.3% | |
| Q3 2023 | -2.0% | — | — | |
| Q2 2023 | -2.0% | — | — | |
| Q1 2023 | -0.4% | — | — | |
| Q4 2022 | +2.3% | — | — | |
| Q3 2022 | +7.9% | — | — | |
| Q2 2022 | +3.3% | — | — | |
| Q1 2022 | -2.8% | — | — | |
| Q4 2021 | +2.7% | — | — | |
| Q3 2021 | +5.4% | — | — | |
| Q2 2021 | -11.6% | — | — | |
| Q1 2021 | +0.6% | — | — | |
| Q4 2020 | +11.6% | — | — | |
| Q3 2020 | -1.4% | — | — | |
| Q2 2020 | +1.5% | — | — | |
| Q1 2020 | -0.7% | — | — | |
| Q4 2019 | -5.5% | — | — | |
| Q3 2019 | -1.3% | — | — | |
| Q2 2019 | +1.1% | — | — | |
| Q1 2019 | +12.7% | — | — | |
| Q4 2018 | +19.8% | — | — | |
| Q3 2018 | -0.8% | — | — | |
| Q2 2018 | -4.5% | — | — | |
| Q1 2018 | -8.9% | — | — | |
| Q4 2017 | +2.1% | — | — | |
| Q3 2017 | +0.0% | — | — | |
| Q2 2017 | -1.2% | — | — | |
| Q1 2017 | -1.5% | — | — | |
| Q4 2016 | -11.4% | — | — | |
| Q3 2016 | +14.4% | — | — | |
| Q2 2016 | -2.7% | — | — | |
| Q1 2016 | +6.0% | — | — | |
| Q4 2015 | +6.9% | — | — | |
| Q3 2015 | -8.0% | — | — | |
| Q2 2015 | +5.0% | — | — | |
| Q1 2015 | — | — | — | |
| Q3 2014 | — | — | — | |
| Q2 2014 | — | — | — | |
| Q4 2013 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro